Ohcanbohtosat - Francisco Vera‐Sempere
- Čájehuvvo 1 - 4 / 4
-
1
-
2
-
3
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis Dahkki Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, L. Aybar García, Jorge A. Guzmán, Carolina Pelayo, Lukas Jürgensen, Ignacio Guzman, Francisco Vera‐Sempere, Lorna Galleguillos, Claudia Cárcamo
Almmustuhtton 2022Artigo -
4
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer Dahkki Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruíz‐Borrego, B. Munarriz, César A. Rodríguez, Carmen Crespo, Enrique de Álava, José Antonio López García‐Asenjo, M. Guitian, Sergio Almenar, Javier González-Palacios, Francisco Vera‐Sempere, José Palacios, Manuel Ramos, Javier Marco, Aña Lluch, Ivonne Álvarez, Miguel Ángel Seguí, José Mayordomo, A. Antón, José Manuel Baena, A. Plazaola, A. Modolell, A. Pelegrí, J. R. Mel, Enrique Aranda, Encarna Adrover, J. V. Alvarez, José Luis García Puche, Pedro Sánchez‐Rovira, Sónia González, José Manuel López-Vega
Almmustuhtton 2008Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Medicine
Chemotherapy
Internal medicine
Alemtuzumab
Cancer
Immunology
Surgery
Adverse effect
Antibody
Bevacizumab
Biology
Botany
Breast cancer
Cancer treatment
Clinical endpoint
Clinical significance
Confidence interval
Cyclophosphamide
Epirubicin
Family medicine
Fingolimod
Fluorouracil
Gerontology
Glatiramer acetate
Graft rejection
Hazard ratio
Hymenoptera
Immunogenicity
Inactivated vaccine
Leukopenia